$0.27
1.43% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Athira Pharma Inc Stock price

$0.27
+0.02 7.80% 1M
-0.37 58.26% 6M
-0.32 54.30% YTD
-2.25 89.36% 1Y
-8.66 97.00% 3Y
-16.73 98.42% 5Y
-16.73 98.42% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.00 1.43%
ISIN
US04746L1044
Symbol
ATHA
Sector
Industry

Key metrics

Market capitalization $10.47m
Enterprise Value $-25.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.29
P/B ratio (TTM) P/B ratio 0.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-78.62m
Free Cash Flow (TTM) Free Cash Flow $-86.06m
Cash position $36.67m
EPS (TTM) EPS $-2.07
P/E forward negative
Short interest 2.61%
Show more

Is Athira Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Athira Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Athira Pharma Inc forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Athira Pharma Inc forecast:

Hold
100%

Financial data from Athira Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.97 0.97
6% 6%
-
-0.97 -0.97
6% 6%
-
- Selling and Administrative Expenses 24 24
21% 21%
-
- Research and Development Expense 53 53
43% 43%
-
-78 -78
37% 37%
-
- Depreciation and Amortization 0.97 0.97
6% 6%
-
EBIT (Operating Income) EBIT -79 -79
37% 37%
-
Net Profit -80 -80
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Athira Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Athira Pharma Inc Stock News

Neutral
GlobeNewsWire
8 days ago
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
Neutral
GlobeNewsWire
11 days ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
Neutral
GlobeNewsWire
3 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
More Athira Pharma Inc News

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.

Head office United States
CEO Mark Litton
Employees 26
Founded 2011
Website www.athira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today